利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.026 秒)

    Immunogenic synthetic glycoconjugate for the immunotherapy of melanoma
    1.
    发明授权
    Immunogenic synthetic glycoconjugate for the immunotherapy of melanoma 有权
    免疫原性合成糖缀合物用于黑色素瘤的免疫治疗

    公开(公告)号：US09255156B2

    公开(公告)日：2016-02-09

    申请号：US14183072

    申请日：2014-02-18

    申请人： Cristina Nativi ,  Lucio Toma ,  Barbara Richichi ,  Carlotta Lunghi

    发明人： Cristina Nativi ,  Lucio Toma ,  Barbara Richichi ,  Carlotta Lunghi

    IPC分类号： A61K38/00 ,  C07K16/44 ,  A61K47/48

    CPC分类号： C07K16/44 ,  A61K47/48092 ,  A61K47/48284 ,  A61K47/4833 ,  A61K47/549 ,  A61K47/643 ,  A61K47/646

    摘要： A specific antibody against a compound of formula (I) wherein X is O, NH, S, CH2; L is a linker that is a divalent spacer; A is an adjuvant or carrier that is an immunogenic molecule or an immunogenic particle; and wherein bonds between linker and saccharide moiety and between linker and carrier are of covalent type; wherein the linker L presents a chemical structure suitable to space the saccharide moiety and the carrier by 7-30 atoms when the adjuvant/carrier A is a biomacromolecule or by 19-30 atoms when the adjuvant/carrier A is a metallic nanoparticle; wherein the carrier/adjuvant A can be selected among a macromolecule, a macrocycle, a dendrimer, a liposome, a nanoparticle, an oligosaccharide featuring from two to five monosaccharidic units or cells like dendritic cells.

    摘要翻译： 一种针对式（I）化合物的特异性抗体，其中X为O，NH，S，CH 2; L是二价间隔基的接头; A是作为免疫原性分子或免疫原性颗粒的佐剂或载体; 并且其中接头和糖部分之间以及接头和载体之间的键是共价型的; 其中当佐剂/载体A为生物大分子时，连接体L呈现适于将糖部分和载体间隔7-30个原子的化学结构，或当佐剂/载体A为金属纳米粒子时，连接体L为19-30个原子。 其中载体/佐剂A可以选自大分子，大环化合物，树状聚合物，脂质体，纳米颗粒，特征在于两至五个单糖单元或细胞如树突状细胞的寡糖。

    Synthetic immunogenic glycoconjugate for melanoma immunotherapy
    2.
    发明授权
    Synthetic immunogenic glycoconjugate for melanoma immunotherapy 失效
    用于黑素瘤免疫治疗的合成免疫原性糖缀合物

    公开(公告)号：US08680043B2

    公开(公告)日：2014-03-25

    申请号：US13505844

    申请日：2010-11-04

    申请人： Cristina Nativi ,  Lucio Toma ,  Barbara Richichi ,  Carlotta Lunghi

    发明人： Cristina Nativi ,  Lucio Toma ,  Barbara Richichi ,  Carlotta Lunghi

    IPC分类号： A01N61/00 ,  A61K31/00 ,  A61K38/00 ,  A61K47/48 ,  A61P35/00

    CPC分类号： C07K16/44 ,  A61K47/48092 ,  A61K47/48284 ,  A61K47/4833 ,  A61K47/549 ,  A61K47/643 ,  A61K47/646

    摘要： The present invention refers to compounds of formula (I) as useful melanoma vaccines' active ingredients. As a matter of fact, compounds of formula (1) are immunogenic artificial antigens, mimetics of GM3 and GM3 lactone, well known tumor associated antigens (TAAs). In addition, the present invention refers to specific antibodies for compounds of formula (I) which are able to bind to the TAAs. The hereinabove reported compounds and antibodies are therefore potentially useful respectively for the active and passive immunization against tumors over-expressing GM3 ganglioside, in a preferred embodiment melanoma and colon cancer, and for their diagnosis and prognosis.

    摘要翻译： 本发明涉及作为有效黑素瘤疫苗活性成分的式（I）化合物。 事实上，式（1）化合物是免疫原性人造抗原，GM3和GM3内酯的模拟物，众所周知的肿瘤相关抗原（TAAs）。 此外，本发明涉及能够结合TAA的式（I）化合物的特异性抗体。 因此，上述报道的化合物和抗体可分别用于针对过表达GM3神经节苷脂的肿瘤的主动和被动免疫，在优选实施方案中，黑素瘤和结肠癌，以及它们的诊断和预后。

    SYNTHETIC IMMUNOGENIC GLYCOCONJUGATE FOR MELANOMA IMMUNOTHERAPY
    3.
    发明申请
    SYNTHETIC IMMUNOGENIC GLYCOCONJUGATE FOR MELANOMA IMMUNOTHERAPY 失效
    MELANOMA IMMUNOTHERAPY的合成免疫球蛋白

    公开(公告)号：US20120263735A1

    公开(公告)日：2012-10-18

    申请号：US13505844

    申请日：2010-11-04

    申请人： Cristina Nativi ,  Lucio Toma ,  Barbara Richichi ,  Carlotta Lunghi

    发明人： Cristina Nativi ,  Lucio Toma ,  Barbara Richichi ,  Carlotta Lunghi

    IPC分类号： A61K39/385 ,  C07K17/10 ,  A61P35/00 ,  C07H15/18 ,  C07K16/18 ,  A61K39/395

    CPC分类号： C07K16/44 ,  A61K47/48092 ,  A61K47/48284 ,  A61K47/4833 ,  A61K47/549 ,  A61K47/643 ,  A61K47/646

    摘要： The present invention refers to compounds of formula (I) as useful melanoma vaccines' active ingredients. As a matter of fact, compounds of formula (I) are immunogenic artificial antigens, mimetics of GM3 and GM3 lactone, well known tumor associated antigens (TAAs). In addition, the present invention refers to specific antibodies for compounds of formula (I) which are able to bind to the TAAs. The hereinabove reported compounds and antibodies are therefore potentially useful respectively for the active and passive immunization against tumors overexpressing GM3 ganglioside, in a preferred embodiment melanoma and colon cancer, and for their diagnosis and prognosis.

    摘要翻译： 本发明涉及作为有效黑素瘤疫苗活性成分的式（I）化合物。 事实上，式（I）化合物是免疫原性人造抗原，GM3和GM3内酯的模拟物，众所周知的肿瘤相关抗原（TAAs）。 此外，本发明涉及能够结合TAA的式（I）化合物的特异性抗体。 因此，上述报导的化合物和抗体分别可用于针对过表达GM3神经节苷脂的肿瘤的主动和被动免疫，在优选实施方案中，黑素瘤和结肠癌，以及它们的诊断和预后。